What is the recommended initial treatment regimen for autoimmune hepatitis?

Recommended Initial Treatment Regimen for Autoimmune Hepatitis

The recommended initial treatment for autoimmune hepatitis is prednisolone 30 mg/day (tapering to 10 mg/day over 4 weeks) combined with azathioprine 1 mg/kg/day, which provides the best balance of efficacy and tolerability while reducing mortality. 1

First-Line Treatment Strategy

Standard Combination Therapy

• Start with prednisolone monotherapy initially at 30-60 mg/day (or up to 1 mg/kg/day in severe cases), then add azathioprine after approximately 2 weeks once bilirubin is below 6 mg/dL (100 μmol/L). 1

• Prednisolone dosing schedule: Begin at 30-60 mg/day, reduce to 50 mg/day after week 1, then 40 mg/day at week 2,30 mg/day at week 3,25 mg/day at week 4,20 mg/day at week 5,15 mg/day at weeks 6-7,12.5 mg/day at weeks 8-9, and maintain at 10 mg/day from week 10 onward. 1

• Azathioprine dosing: Start at 50 mg/day when added (typically week 2-3), then increase to maintenance dose of 100 mg/day (1-2 mg/kg body weight) based on tolerance and response. 1

• Delaying azathioprine introduction by 2 weeks is pragmatic as it helps resolve diagnostic uncertainties and avoids confusion between azathioprine-induced hepatotoxicity and primary non-response. 1

Evidence Supporting Combination Therapy

• Mortality reduction is substantial: Prednisolone-based treatment reduces death/transplantation rates compared to no treatment (RR 0.38,95% CI 0.20-0.74), with benefits seen in asymptomatic patients, those without cirrhosis, and even those with decompensated cirrhosis. 2

• Combination therapy superior to monotherapy: Prednisolone plus azathioprine reduces death/transplantation compared to prednisolone alone (RR 0.38,95% CI 0.22-0.65). 2

• Historical controlled trials demonstrated: Mortality rates of 6-7% with prednisolone or combination therapy versus 41% with placebo, with combination therapy causing fewer side effects (10% vs 44%). 1

Pre-Treatment Considerations

TPMT Testing

• Measure thiopurine methyltransferase (TPMT) activity before starting azathioprine to exclude homozygote TPMT deficiency, particularly in patients with pre-existing leucopenia. 1

Bone Protection

• Initiate calcium and vitamin D supplementation immediately when starting corticosteroids. 1

• Perform DEXA bone scanning at 1-2 yearly intervals while on steroids and actively treat osteopenia/osteoporosis. 1

Vaccination

• Vaccinate against hepatitis A and hepatitis B early in susceptible patients. 1

Alternative First-Line Regimens for Specific Populations

Non-Cirrhotic Patients at High Risk for Steroid Side Effects

• Budesonide 9 mg/day plus azathioprine may be considered in treatment-naïve non-cirrhotic patients with early-stage disease who are at high risk for steroid-specific side effects (post-menopausal women, emotional instability, pre-existing osteoporosis, brittle diabetes, labile hypertension, obesity, young women concerned about cosmetic effects). 1

• Budesonide achieves similar biochemical response rates to prednisolone (RR 0.99,95% CI 0.71-1.39) with significantly fewer cosmetic adverse effects (RR 0.46,95% CI 0.34-0.62). 2, 3

• Critical contraindication: Budesonide should NOT be used in cirrhotic patients or those with peri-hepatic shunting due to loss of first-pass hepatic metabolism and risk of systemic side effects. 1

Azathioprine Intolerance

• If azathioprine is not tolerated: Use prednisolone monotherapy at higher doses (60 mg/day reducing to 20 mg/day over 4 weeks), though this often causes more side effects. 1

• Alternative option: Prednisolone 10-20 mg/day plus mycophenolate mofetil, which achieves similar biochemical response rates to azathioprine (RR 1.32,95% CI 0.73-2.38) with fewer adverse effects requiring drug cessation (RR 0.20,95% CI 0.09-0.43). 1, 2

Dosing Considerations and Common Pitfalls

Higher Initial Steroid Doses

• Higher initial prednisolone doses (up to 1 mg/kg/day) may result in more rapid normalization of transaminases but do not improve overall biochemical response rates (RR 1.07,95% CI 0.92-1.24) or mortality (RR 0.71,95% CI 0.25-2.05), while causing significantly more adverse effects (RR 1.73,95% CI 1.17-2.55). 2

• Exercise caution in frail elderly patients when using higher steroid doses. 1

Azathioprine Monotherapy

• Never use azathioprine as monotherapy for induction as it is associated with high mortality rates (30%) and is not viable as initial treatment. 4

Severe Presentations Requiring Modified Approach

Acute Severe AIH

• Treat with high-dose intravenous corticosteroids (≥1 mg/kg or up to 100 mg prednisolone IV) as early as possible. 1

• If no improvement within 7 days (or 2 weeks per AASLD): List for emergency liver transplantation. 1

Acute Liver Failure

• Patients with AIH presenting as acute liver failure should be evaluated directly for liver transplantation. 1

• Corticosteroid trial may be considered (prednisone 40-60 mg/day) while simultaneously listing for transplant, though recovery without transplantation is uncommon. 1

Liver Failure, Bridging Necrosis, or High MELD Score

• Contact a liver transplant center immediately if patients present with liver failure, bridging necrosis on biopsy, or jaundice with MELD score that does not rapidly improve on treatment. 1

Treatment Duration and Monitoring

Minimum Treatment Duration

• Continue azathioprine 1 mg/kg/day and prednisolone 5-10 mg/day for at least 2 years and for at least 12 months after normalization of transaminases. 1

Treatment Goals

• Aim for complete biochemical AND histological remission: Normalization of both transaminases and IgG levels, as persistent elevations predict relapse, progression to cirrhosis, and poor outcome. 1

• Histological remission typically lags behind biochemical remission by several months (achieved in 75% after 18 months of treatment). 1

Management of Inadequate Response

Non-Response or Slow Response

• First reconsider the diagnosis and re-evaluate adherence to treatment before escalating therapy, particularly in young, non-Caucasian patients with acute presentations. 1

• If confirmed AIH with inadequate response: Increase azathioprine to 2 mg/kg/day combined with prednisolone 5-10 mg/day, or consider alternative agents (tacrolimus, cyclosporine), but seek expert advice. 1

• Mycophenolate mofetil has limited efficacy in refractory disease (23% response rate) but is more effective for azathioprine intolerance (58% response rate). 1

This evidence-based approach prioritizes mortality reduction and quality of life while minimizing treatment-related complications through strategic use of combination therapy and appropriate patient selection for alternative regimens.